

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>OrbiMed Israel BioFund GP Limited Partnership</u> (Last) (First) (Middle) 5 HAHOSHLIM STREET, BUILDING B, 1ST FL. (Street) HERZLIYA L3 46686 PITUACH (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BiomX Inc. [PHGE]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 03/15/2024	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series X Preferred Stock	(1)(2)	03/15/2024		P		4,327		(1)(2)	(1)(2)	Common Stock	4,327,000	(1)(2)	4,327	I	See footnotes ⁽⁴⁾⁽⁵⁾
Warrants (Right to Buy)	\$0.2311	03/15/2024		P		2,163,500		(3)	(3)	Common Stock	2,163,500	(3)	2,163,500	I	See footnotes ⁽⁴⁾⁽⁵⁾

1. Name and Address of Reporting Person * <u>OrbiMed Israel BioFund GP Limited Partnership</u> (Last) (First) (Middle) 5 HAHOSHLIM STREET, BUILDING B, 1ST FL. (Street) HERZLIYA L3 46686 PITUACH (City) (State) (Zip)
1. Name and Address of Reporting Person * <u>OrbiMed Israel GP Ltd.</u> (Last) (First) (Middle) 5 HAHOSHLIM STREET, BUILDING B, 1ST FL. (Street) HERZLIYA L3 46686 PITUACH (City) (State) (Zip)

